FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used to create an experimental model of glaucoma in rats. A 3 % solution of 7-ethyl-2-methyl-4-undecanol hydrogensulphate sodium salt 0.1 ml is introduced into an anterior eye chamber.
EFFECT: method provides optimization of the glaucoma induction method and is characterized by technical simplicity as a result of introducing into the anterior eye chamber 3 % solution of 7-ethyl-2-methyl-4-undecanol hydrogensulphate sodium salt, which has surface-active properties (anionic surfactant detergent), is a venosclerosis preparation and enables to accelerate simulation of experimental glaucoma.
1 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CREATING EXPERIMENTAL GLAUCOMA MODEL | 1998 |
|
RU2164396C2 |
| METHOD FOR SIMULATING ANTERIOR SEGMENT NEOVASCULARISATION IN RATS | 2012 |
|
RU2488891C1 |
| METHOD FOR COMBINED TREATMENT OF SECONDARY NEOVASCULAR GLAUCOMA | 2022 |
|
RU2786144C1 |
| DISULFIRAM AND TAURINE-CONTAINING OPHTHALMOLOGICAL MEDICATION IN FORM OF EYE DROPS | 2012 |
|
RU2485939C1 |
| METHOD OF COMBINED TREATMENT OF SEVERE FORMS OF SECONDARY NEOVASCULAR GLAUCOMA | 2019 |
|
RU2708059C1 |
| METHOD OF TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS | 2014 |
|
RU2577236C1 |
| AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
| GLAUCOMA TREATMENT | 2018 |
|
RU2759998C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIALLERGIC ACTION | 2012 |
|
RU2488402C1 |
